Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

Conference Paper

Full Text

Link to Item

Duke Authors

Salama, April Kelly Scott

Cited Authors

Middleton, MR; Hamid, O; Shoushtari, AN; Meier, FE; Bauer, TM; Salama, AKS; Kirkwood, JM; Ascierto, PA; Lorigan, P; Mauch, C; Orloff, MM; Evans, TRJ; Abdullah, SE; Yuan, Y; Mitchell, J; Hassel, JC

Published Date

2022

Published In

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Volume / Issue

40 / 16

Electronic International Standard Serial Number (EISSN)

1527-7755

International Standard Serial Number (ISSN)

0732-183X